Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Abbott cholesterol drug meets primary endpoints

Abbott cholesterol drug meets primary endpoints

1st April 2008

Abbott has announced the results of a phase III clinical trial of its investigational compound TriLipix (fenofibric acid), formerly known as ABT-335, used in combinaiton with statins.

Study results presented at the American College of Cardiology show that the compound improved LDL cholesterol, triglycerides and HDL cholesterol compared to corresponding monotherapies.

The trial used the drug in conjunction with atorvastatin and simvastatin, with the treatment reaching its primary endpoints, with triglycerides and HDL improved compared to the sole use of statin therapy and LDL levels improved compared to the sole use of TriLipix.

Further detail regarding the compound is planned for publication and various scientific forums throughout the year.

Eugene Sun, vice-president of global pharmaceutical clinical development at Abbott, said: “Through our investment in a broad clinical development program for TriLipix, Abbott is providing physicians with data to help support a potential new treatment option for their patients.”

Christie Ballantyne of the Methodist DeBakey Heart and Vascular Centre in Houston said that only a quarter of patients taking lipid-altering therapies currently reach their treatment goals.

Earlier this month, Solvay paid a a $100 million (49.3 million pound) milestone payment to Abbott following regulatory progress in Simcor (Niaspan/simvastatin).

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.